Allarity Therapeutics, Inc. (ALLR) Financial Statements (2026 and earlier)

Company Profile

Business Address 24 SCHOOL ST., 2ND FLOOR
BOSTON, MA 02108
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments14,68719,5331662,02919,555
Cash and cash equivalent14,68719,5331662,02919,555
Restricted cash and investments     
Receivables866770815  
Prepaid expense2,11050778159136
Other current assets2651152091,559625
Other undisclosed current assets  1,416 789838
Total current assets:17,92822,3411,9714,96821,054
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization    686
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization33030920218
Long-term investments and receivables     350
Long-term investments     350
Intangible asset, including goodwill, after accumulated amortization   9,8719,54928,135
Intangible asset, excluding goodwill, after accumulated amortization   9,8719,54928,135
Total noncurrent assets:3303099,8919,57628,579
TOTAL ASSETS:18,25822,65011,86214,54449,633
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,9499,4149,7258,15510,489
Taxes payable✕✕✕✕✕113
Employee-related liabilities✕✕✕✕✕1,088
Accounts payable4,2824,1828,4166,251698
Accrued liabilities2,6675,2321,3091,9048,590
Debt1,4001,3502502,6441,000
Derivative instruments and hedges, liabilities  13,08337474
Other undisclosed current liabilities81741,109499,156
Total current liabilities:8,43010,83914,16711,22220,719
Noncurrent Liabilities
Long-term debt and lease obligation:     9
Liabilities, other than long-term debt   4461,43210,121
Accumulated deferred investment tax credit    1,083979
Deferred income tax liabilities   4463491,961
Operating lease, liability     9
Derivative instruments and hedges, liabilities     7,181
Total noncurrent liabilities:   4461,43210,130
Total liabilities:8,43010,83914,61312,65430,849
Temporary equity, including noncontrolling interest    2,003 
Equity
Equity, attributable to parent9,82811,811(2,751)(113)18,152
Preferred stock   1,742  
Common stock31 2810
Treasury stock, value(3,190)    
Additional paid in capital144,233131,13090,36983,15684,434
Accumulated other comprehensive loss(1,021)(354)(411)(721)(600)
Accumulated deficit(130,197)(118,966)(94,451)(82,550)(66,492)
Other undisclosed equity     632
Total equity:9,82811,811(2,751)(113)18,784
TOTAL LIABILITIES AND EQUITY:18,25822,65011,86214,54449,633

Income Statement (P&L) ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenues320    
Cost of revenue
(Financing Interest Expense)
    (51)(51)
Gross profit:320  (51)(51)
Operating expenses(12,925)(27,241)(17,129)(34,463)(26,556)
Other undisclosed operating income   5151
Operating loss:(12,605)(27,241)(17,129)(34,463)(26,556)
Nonoperating income (expense)1,3742,3455,31116,884(549)
Investment income, nonoperating80153322(85)(495)
Gain (loss), foreign currency transaction, before tax757(212)133(913)(95)
Interest and debt expense(185)(653)(217)(12)(99)
Loss from continuing operations before equity method investments, income taxes:(11,416)(25,549)(12,035)(17,591)(27,204)
Other undisclosed income from continuing operations before income taxes185653217  
Loss from continuing operations before income taxes:(11,231)(24,896)(11,818)(17,591)(27,204)
Income tax expense (benefit)  381(83)1,521(133)
Loss from continuing operations:(11,231)(24,515)(11,901)(16,070)(27,337)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(27,337)
Other undisclosed net income    12689
Net loss:(11,231)(24,515)(11,901)(16,058)(26,648)
Other undisclosed net income attributable to parent     
Net loss attributable to parent:(11,231)(24,515)(11,901)(16,058)(26,648)
Preferred stock dividends and other adjustments   (8,515)(5,947) 
Other undisclosed net income (loss) available to common stockholders, basic  (639) 5,947 
Net loss available to common stockholders, basic:(11,231)(25,154)(20,416)(16,058)(26,648)
Dilutive securities, effect on basic earnings per share   2,667  
Net loss available to common stockholders, diluted:(11,231)(25,154)(17,749)(16,058)(26,648)

Comprehensive Income ($ in thousands)

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Net loss:(11,231)(24,515)(11,901)(16,058)(26,648)
Other comprehensive income (loss)(667)57(310)1211,966
Other undisclosed comprehensive loss     
Comprehensive loss:(11,898)(24,458)(12,211)(15,937)(24,682)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  620(242)(3,941)
Comprehensive loss, net of tax, attributable to parent:(11,898)(24,458)(11,591)(16,179)(28,623)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.